BLAINJECTIONINJECTABLEPriority Review
Approved
Jul 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
KISUNLA (donanemab-azbt) by Eli Lilly and Company is donanemab-azbt is a humanized immunoglobulin gamma 1 (igg1) monoclonal antibody directed against insoluble n-truncated pyroglutamate amyloid beta. First approved in 2024.
Drug data last refreshed 3d ago
Mechanism of Action
Donanemab-azbt is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against insoluble N-truncated pyroglutamate amyloid beta. The accumulation of amyloid beta plaques in the brain is a defining pathophysiological feature of Alzheimer's disease. Donanemab-azbt reduces amyloid…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Company
Eli Lilly and Company
Worked on KISUNLA at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.